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Voxelwise Mapping of Whole-Exome
Sequencing to Noninvasive Imaging with
Stereotactic Localization and Deep
Learning

With the use of Artificial Intelligence,
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95% of Glioblastoma patients die within five years. Other gliomas are similarly
fatal with high levels of recurrence after treatment.
Gliomas are primarily treated by surgical resection followed by chemotherapy and
radiation. Post-surgical histology reveals relevant mutations in the tumor cells,
allowing for the selection of specified chemotherapy drugs.
However, drug effectiveness is limited by tumor heterogeneity.
Gliomas are not homogenous masses of invasive cells but are heterogenous
groups of cancer cells with varying mutations.
Post-surgical histology is only representative of a small tumor subpopulation, and
specified drug treatment fails to treat other cell populations. On account of this
heterogeneity, tumors recur after treatment.
With improved detection of tumor heterogeneity, oncologists could select more
specified drug treatments, thereby improving glioma recurrence and survival rates.
Current biopsy and histology methods fail to adequately detect tumor
heterogeneity. In the future, MRI imaging coupled with artificial intelligence
could more effectively detect heterogeneity.
To further develop this idea, we conducted a retrospective study, analyzing brain
scans and biopsy samples for ten glioma patients.

Magnetic Resonance Imaging (MRI)
can characterize brain tumor
heterogeneity.

METHODS:
1. Identification of 10 glioma patients from an ongoing neurosurgery study according
to IRB protocols. Consent was waived on account of the retrospective nature of
the study. All PHI remained confidential.
2. Patients included had an MRI scan with at least five series: T1, T2, T2 FLAIR, DWI,
and T2 with contrast.
3. During surgical resection of the glioma, stereotactic localization (see center figure)
of up to four tumor tissue samples was captured each patient. Such localization
enabled pairing of biopsy location with the corresponding coordinates on the MR
scan.
4. Each biopsy sample was sent to CHOP for DNA sequencing, and analysis centered
on eight gene targets which are commonly mutated in glioma patients.
5. DNA sequencing analysis and MR images were fed into a 3-layer neural network.
After the neural network was trained via cross validation and the leave-one-out
process, we tested its accuracy.

RESULTS:
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DISCUSSION:
•
•
•
•

Testing accuracy of 76.5% shows that our neural network can effectively predict
mutations in tumor subpopulations from MR images.
Future studies are needed to train the neural network with more patients and
potentially more mutations.
We are working to choose mRNA and DNA methylation targets so that our neural
network can detect changes in expression and methylation patterns.
We are in the process of obtaining IRB approval for a prospective study which
includes more patients and uses stereotactic core biopsy, an improvement on the
stereotactic techniques used in this paper.
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